RATIONALE: Identification of key driver genes of severe asthma could highlight novel mechanistic pathways and therapeutic targets for this condition. METHODS: We recruited 33 severe asthmatic children and 122 controls for nasal brushing. Severe asthma genes were identified using RNA sequencing and differential expression analysis. To characterize the biologic context for these genes, a weighted gene co-expression network was constructed, and co-expression modules enriched for severe asthma genes were identified. Member genes of enriched modules were used to build causal probabilistic Bayesian networks. Key drivers of these networks were identified as causal regulators of the regulatory states of these networks. Results were tested in an independent asthma cohort (n5187). RESULTS: We identified 264 severe asthma genes (absolute log 2 -foldchange > _ 1, FDR< _0.05), of which 101 were over-expressed and 163 were under-expressed in severe asthma vs. controls. These genes were significantly over-represented in co-expression modules enriched for inflammatory response and cilium function. Bayesian network construction and key driver analysis identified five causal key drivers (DOCK11, EVI2B, GBP5, PRTRC, RGS2) of the inflammatory response module enriched for over-expressed severe asthma genes. These five genes are predicted to modulate leukocyte function. Eight causal key driver genes (C20orf85, CCDC108, CCDC17, DNAI2, FAM92B, LRRC71, TEKT2, ZMYND10) were identified for the cilium module enriched for under-expressed severe asthma genes. These eight genes are predicted to modulate the structure and movement of respiratory cilia. The key driver findings replicated in the independent cohort. CONCLUSIONS: Thirteen key driver genes encompassing leukocyte function and respiratory cilia movement represent high-yield therapeutic targets for severe asthma.
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